Advertisement
U.S. markets open in 3 hours 49 minutes

Curative Biotechnology, Inc. (CUBT)

Other OTC - Other OTC Delayed Price. Currency in USD
0.0285-0.0005 (-1.72%)
At close: 03:59PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0290
Open0.0299
BidN/A x N/A
AskN/A x N/A
Day's Range0.0277 - 0.0300
52 Week Range0.0051 - 0.0400
Volume62,150
Avg. Volume279,600
Market Cap15.652M
Beta (5Y Monthly)220.27
PE Ratio (TTM)N/A
EPS (TTM)-0.0100
Earnings DateMar 19, 2024 - Mar 23, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for CUBT

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • CURATIVE BIOTECHNOLOGY INC
    Weekly Stock ListWe see what we believe are some great opportunities right now in Healthcare -- and we like the sector overall. Argus Director of Research Jim Kelleher, CFA, recently completed his quarterly sector review and raised Healthcare sector to Over-Weight from Market-Weight. The healthcare environment is undergoing rapid transitions, and we now see an unfolding period of significant promise and opportunity. Our newly-favored stance is based on resumption of deferred medical procedures and significant new quality-of-life drugs and treatments. The category is broad and has underperformed the S&P 500 over the past year. The Healthcare sector ETF (XLV) is up 15% over the past year compared to a gain of 31% for the S&P 500. We see opportunity here to pick up some steady companies, with big brands and solid financials. These companies are science-focused and enhance lives. They are innovators. In our list this week, we look across several subsectors within the Healthcare sector and pull out some leaders we like. These stocks also are included in our Focus List and Model Portfolios, as noted below.
    Rating
    Fair Value
    Economic Moat
    22 hours agoArgus Research
View more
  • GlobeNewswire

    Curative Biotechnology, Inc. Announces Nomination of Dr. Theresa Heah to Board of Directors

    Appointment of Independent Director Nominee to become effective upon approval by and listing of common stock on a National Exchange Boca Raton, FL, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company focused on novel treatments for degenerative eye diseases today announced its nomination to its Board of Directors of Dr. Theresa Heah. Dr. Heah is expected to join its Board of Directors as an indepe

  • GlobeNewswire

    Curative Biotechnology, Inc. Announces Nomination of Dr. Jeffrey Liebmann to Board of Directors

    Appointment of Independent Director to become effective upon approval by and listing of common stock on a National Exchange Boca Raton, FL, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company focused on novel treatments for degenerative eye diseases today announced its nomination to its Board of Directors of Dr. Jeffrey Liebmann. Dr. Liebmann is expected to join its Board of Directors as an indepe

  • GlobeNewswire

    Curative Biotechnology Announces Establishment of Japanese Subsidiary for Licensing Transactions and Asset Acquisitions

    Appoints Paul Michaels Co-CEO of Parent and CEO of Subsidiary Boca Raton, FL, June 06, 2023 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company focused on novel therapies for rare diseases and conditions, today announced that the registration process has begun for the creation of a subsidiary in Japan with an official incorporation date expected August 1, 2023, to facilitate licensing transactions and asset lic